50th week of 2009 patent applcation highlights part 40 |
Patent application number | Title | Published |
20090304715 | MODIFIED ANTIBODIES WITH ENHANCED BIOLOGICAL ACTIVITIES - The present inventors generated modified antibodies in which several Fc domains are linked in tandem to the C terminus of the heavy chain, and modified antibodies in which Fc domains are linked in tandem via spacers, and measured the affinity for Fc receptors, CDC activity, and ADCC activity. A previous report indicated that CDC activity is not enhanced by linking multiple Fcs. However, the modified antibodies of the present invention exhibited enhanced ADCC activity. The methods of the present invention enable provision of antibody pharmaceuticals having a marked therapeutic effect. | 2009-12-10 |
20090304716 | TREATMENT OF METASTATIC BREAST CANCER - The present invention relates to the use of an anti-EpCAM antibody for the manufacture of a medicament for the treatment of metastatic breast cancer. The present invention further relates to a method of treating metastatic breast cancer comprising administering said anti-EpCAM antibody. | 2009-12-10 |
20090304717 | Immuno-RNA-Constructs - Subject of the invention is a compound, consisting of a targeting moiety which specifically binds to a disease related cell surface marker, a nucleic acid which specifically induces cell death and a linker, wherein the linker covalently links the targeting moiety to the nucleic acid. Subject of the invention are also medicaments comprising the compound and their use as a medicament for the treatment of diseases, including proliferative diseases. | 2009-12-10 |
20090304718 | Antibody Molecules Specific for Fibroblast Activation Protein and Immunoconjugates Containing Them - Anti-FAP-antibodies and immunoconjugates, pharmaceutical compositions containing such conjugates, and their use in cancer therapy. | 2009-12-10 |
20090304719 | ACTIVATABLE BINDING POLYPEPTIDES AND METHODS OF IDENTIFICATION AND USE THEREOF - The present disclosure provides activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM). The present disclosure provides activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM. Furthermore the present disclosure also provides ABPs which contain a first TBM, a second TBM and a CM. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. The disclosure further provides libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. The disclosure further provides ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use. | 2009-12-10 |
20090304720 | Active Agent-Loaded Nanoparticles Based On Hydrophilic Proteins - Active agent-loaded nanoparticles that are based on a hydrophilic protein or a combination of hydrophilic proteins, and methods for producing the nanoparticles and the use thereof. Functional proteins or peptide fragments are bound to the nanoparticles via polyethylene glycol-α-maleimide-ω-NHS esters. | 2009-12-10 |
20090304721 | TOXIN CONJUGATED EPH RECEPTOR ANTIBODIES - The present invention relates to compositions and methods for inducing cell death or stasis in cancer cells or other hyperproliferative cells using anti-EphA2 or anti-EphA4 antibodies conjugated to toxins. | 2009-12-10 |
20090304722 | CHLAMYDIA TRACHOMATIS ANTIGENS FOR VACCINE AND DIAGNOSTIC USE - The present invention is related to antigens from | 2009-12-10 |
20090304723 | Mono-and disaccharide derivatives - The present invention relates to a novel family of monosaccharide derivatives and disaccharide derivatives and to a method of preparation thereof. A mono- and disaccharide derivatives according to the invention comprises at least one fatty acid ester and may further comprise one or more anionic groups and are useful for, inter alia, medical, pharmaceutical, cosmetic and food applications. | 2009-12-10 |
20090304724 | Compositions and Methods for Stimulating Gastrointestinal Motility - The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient. | 2009-12-10 |
20090304725 | Vaccine and Antigen Mimotopes Against Cancerous Diseases Associated with the Carcinoembryonic Antigen CEA - The present invention relates to a vaccine against cancerous diseases associated with the carcinoembryonic antigen CEA. | 2009-12-10 |
20090304726 | VIRAL DISPLAY VEHICLES FOR TREATING MULTIPLE SCLEROSIS - Provided are viral display vehicles which display multiple sclerosis associated antigens on the surface thereof for induction of immune tolerance to autoantigens such as MOG. Also provided are methods and pharmaceutical compositions for treating multiple sclerosis using the viral display vehicles of the present invention. | 2009-12-10 |
20090304727 | HYPOALLERGENIC CHIMERIC PROTEINS BELONGING TO THE LIPID TRANSFER FAMILY OF PARIETARIA JUDAICA FOR USE IN THE TREATMENT OF ALLERGIES - The present invention relates to recombinant DNA molecules which encode chimeric polypeptides of differing allergens of | 2009-12-10 |
20090304728 | TEM8 GENE, EXPRESSION FORMS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF - The present invention relates to the modulation of a gene known as “tumor endothelial marker 8 (TEM8)” and refers to the differential levels with which the gene is expressed, in its variants, in cells exhibiting angiogenic and migratory properties such as dendritic cells and metastatic tumor cells. The present invention further relates to the use of gene and polypeptide sequences of TEM8 as instruments of diagnosis and prognosis of pathological inflammatory angiogenesis and of the metastatic potential of tumor cells. The invention further relates to the use of the same gene and polypeptide sequences as direct therapeutic instruments, and to the use in immunogenic compositions or in vaccines apt to induce an immune response against cells overexpressing TEM8 gene products. Furthermore, the present invention relates to screening methods for identifying agonists and antagonists of TEM8 activity in any polynucleotide and/or polypeptide variant thereof to be used in prevention or therapy treatments. Lastly TEM8 expression profiles in in vitro expanded DCs from cancer patients intercepts responsiveness to cancer immunotherapy. | 2009-12-10 |
20090304729 | CELL-DERIVED VIRAL VACCINES WITH LOW LEVELS OF RESIDUAL CELL DNA - The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by treatment with a DNA alkylating agent, such as β-propiolactone (BPL), thereby providing a vaccine comprising immunogenic proteins derived from a virus propagated on cell culture, substantially free of residual functional cell culture DNA. | 2009-12-10 |
20090304730 | INFLUENZA VACCINE - The present invention relates to influenza vaccines for human and veterinary use. In particular, the present invention provides a vaccine able to effect long term and cross-strain protection by including at least two influenza virus epitopes expressed as a chimeric polypeptide wherein at least one epitope is influenza A virus matrix protein epitope and the second epitope is a haemagglutinin peptide epitope. | 2009-12-10 |
20090304731 | RECOMBINANT ANTIGENS FOR DIAGNOSIS AND PREVENTION OF SPOTTED FEVER RICKETTSIAE - The invention relates to the construction of recombinant, immunodominant polypeptides against spotted fever group | 2009-12-10 |
20090304732 | Cryptosporidium Hominis Genes and Gene Products for Chemotherapeutic, Immunoprophylactic and Diagnostic Applications - genes and gene products are provided. The genes and gene products are useful for chemotherapeutic, immunotherapeutic, immunoprophylactic and diagnostic applications. | 2009-12-10 |
20090304733 | Vaccine comprising recombinant ct or lt toxin - The present invention provides a recombinant toxin or the subunit B thereof selected from the group consisting of | 2009-12-10 |
20090304734 | IMMUNOGENS FOR MENINGITIDIS-A VACCINES - An oligosaccharide useful for a Meningitidis A vaccine contains a first mannose unit having a spacer in the alpha configuration at C-1, which spacer is capable of conjugating to a protein, and which is connected to a second mannose unit through a 1,6-linkage which connects C-6 of the first unit to C-1 of the second unit, wherein the 1,6-linkage comprises a phosphonate. Related methods of making such compounds, analogous compounds, or intermediates thereof are also disclosed. | 2009-12-10 |
20090304735 | Immunogenic Compositions - The present invention relates to an immunogenic composition for raising an immune response to an antigen, the composition comprising the antigen and a targeting moiety specific for lymph-resident dendritic cells. Use of the immunogenic composition in a vaccine and methods of boosting an immune response using the composition are also provided. Conversely, the invention also relates to immunogenic composition for raising an immune response to an antigen, the composition comprising the antigen and a targeting moiety specific for tissue-derived dendritic cells and a vaccine comprising said composition. | 2009-12-10 |
20090304736 | NOVEL TUMOR ANTIGENS ELICIT ANTI-TUMOR HUMORAL IMMUNE REACTIONS IN A SUBSET OF PATIENTS WITH POLYCYTHEMIA VERA - The invention provides novel antigens, MPD5, PV13, and PV65, which belongs to the group of cryptic antigens without conventional genomic structure and is encoded by a cryptic open reading frame located in the 3′untranslated region (3′UTR) of myotrophin mRNA. The antigens elicit IgG antibody responses in a subset of PV patients, as well as patients with chronic myelogenous leukemia and prostate cancer. The translation of MPD5, PV13 and PV65 was mediated by a novel internal ribosome entry site (IRES) upstream of the open reading frame. Eliciting anti-tumor immune response against MPD5, PV13 and/or PV65 antigen in patients with myeloproliferative diseases is a novel immunotherapy. | 2009-12-10 |
20090304737 | Vaccine Against Mycoplasma PRRSV - The present invention relates to the use of an immunogenic dose of immunogenic material of | 2009-12-10 |
20090304738 | Methods for Enhancing Immune Responses - The present invention is directed to methods for enhancing immune responses. Such methods serve to enhance dendritic cell activation, which, in turn, promotes a more robust immune response to foreign antigens. As such, the methods and compositions of the invention are for useful in the context of a variety of prophylactic and therapeutic regimens. | 2009-12-10 |
20090304739 | INFLUENZA VACCINES INCLUDING COMBINATIONS OF PARTICULATE ADJUVANTS AND IMMUNOPOTENTIATORS - Influenza vaccines containing insoluble particulate adjuvants have been found to elicit an IgG response that is primarily a TH2 response (IgG1). This response can be shifted towards a TH1 response (IgG2a) by including immunopotentiators in the compositions. Thus the invention provides an immunogenic composition comprising: (i) an influenza virus antigen; (ii) an insoluble particulate adjuvant; and (iii) a immunopotentiator. | 2009-12-10 |
20090304740 | MODIFIED HIV ENV POLYPEPTIDES - Polynucleotide encoding modified HIV Env polypeptides are disclosed. The Env polypeptides are modified so as to expose at least part of the CD4 binding region. Methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided. | 2009-12-10 |
20090304741 | Yeast-Dendritic Cell Vaccines and Uses Thereof - Disclosed is a vaccine that includes a dendritic cell loaded with a yeast vehicle and antigen. Also disclosed are methods of making the vaccine and using the vaccine to elicit cellular and humoral immune responses in a mammal. Additionally, a method to elicit an immune response by administration of a yeast vehicle and an antigen that is not complexed to the yeast vehicle is disclosed. | 2009-12-10 |
20090304742 | INFLUENZA VACCINES WITH REDUCED AMOUNT OF EMULSION ADJUVANT - Influenza vaccines with oil-in-water emulsion adjuvants are known. The amount of emulsion adjuvant required for an influenza vaccine can be reduced, thereby allowing more vaccines to be made from a given amount of emulsion, and/or minimizing the amount of emulsion that has to be produced for a given number of vaccine doses. These vaccines can conveniently be made by mixing (i) an oil-in-water emulsion and (ii) an aqueous preparation of an influenza virus antigen. In one aspect, substantially equal volumes of components (i) and (ii) are used; in another aspect, an excess volume of component (ii) is used. When using substantially equal volumes, component (ii) has a hemagglutinin concentration of more than 60 μg influenza virus strain per ml. Components (i) and (ii) can be presented in kit form. | 2009-12-10 |
20090304743 | Composition and Methods for Immunisation Using CD1D Ligands - The invention relates to immunogenic compositions containing CD1d ligands that induce long-term immunological memory in the absence of booster doses and/or in the absence of multiple priming doses. The invention further relates to immunogenic compositions containing CD1d ligands and antigens from influenza virus, group B | 2009-12-10 |
20090304744 | METHODS OF ENHANCING IMMUNE RESPONSE IN THE INTRADERMAL COMPARTMENT AND COMPOUNDS USEFUL THEREOF - The present invention relates to immunogenic compositions for intradermal delivery of an antigenic or immunogenic agent in combination with one or more excipients. The immunogenic compositions of the invention comprise an antigenic or immunogenic agent and at least one excipient which acts as an adjuvant, i.e., enhances the immune response to the antigenic or immunogenic agent, once delivered to the intradermal compartment of a subject's skin. The immunogenic compositions of the invention comprise an excipient which when administered to the intradermal compartment of skin in accordance with the invention demonstrate adjuvant activity. The immunogenic compositions of the invention have enhanced efficacy as the excipients of the composition cause an asymptomatic skin irritation and recruit antigen presenting cells to the intradermal compartment and thus enhance presentation and/or availability of the antigenic or immunogenic agent to the antigen presenting cells. The enhanced efficacy of the immunogenic compositions of the invention may result in a therapeutically effective immune response after a single intradermal dose, with lower doses of antigenic or immunogenic agent than conventionally used, and without the need for booster immunizations. | 2009-12-10 |
20090304745 | CHIMERIC ALPHAVIRUS REPLICON PARTICLES - Chimeric alphavirus particles and alphavirus replicon RNAs are provided including methods of making and using same. The alphavirus replicon RNAs comprise deletions in one or more nonstructural proteins. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle are disclosed. | 2009-12-10 |
20090304746 | Inducing cellar immune responses to hepatitis C virus using peptide and nucleic acid compositions - This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare HCV epitopes, and to develop epitope-based vaccines directed towards HCV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HCV infection. | 2009-12-10 |
20090304748 | CLOSTRIDIAL TOXIN PHARMACEUTICAL COMPOSITIONS | 2009-12-10 |
20090304749 | Method of Producing Rough Strains of Bacteria and Uses Thereof - The present invention relates to a method of producing rough strains of a bacterium, such as | 2009-12-10 |
20090304750 | NOVEL PRIME-BOOST COMBINATIONS OF ATTENUATED MYCOBACTERIUM - The present invention provides vaccine compositions for effective induction of both mucosal and systemic immunity to pathogenic | 2009-12-10 |
20090304751 | VAULT COMPOSITIONS FOR IMMUNIZATION AGAINST CHLAMYDIA GENITAL INFECTION - Methods and compositions are provided herein for immunizing a subject against Chlamydial genital infection by administering to the subject an effective amount of a Chlamydial immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. In some aspects, the vault-like-particles are administered to the nasal mucosa. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity at mucosal surfaces while reducing inflammation associated with | 2009-12-10 |
20090304752 | HYPOALLERGENIC VARIANTS OF THE MAJOR ALLERGEN FROM BETULA VERRUCOSA POLLEN - The invention provides hypoallergenic variants of Bet v 1 major allergen from | 2009-12-10 |
20090304753 | Method and Apparatus For Forming Delivery Devices For Oral Intake of an Agent - Methods, systems and apparatuses are provided for producing delivery devices, preferably for oral intake of an agent. In the broadest aspect, the method comprises assembling one or more layers comprising one or more materials with an agent or an agent-releasing formulation to form an intergraded, preferably laminated device; folding said integrated delivery device to form a folded integrated delivery device; and at least partially enclosing said folded delivery device to a form suitable for oral delivery. Preferably, the integrated device comprise a first external layer of a first material; a frame of a second material mounted on the first external layer; an agent-releasing formulation housed within the frame; and a second external layer of the first material mounted on the frame. | 2009-12-10 |
20090304754 | Pegylated glutenase polypeptides - Glutenase proteins, such as prolyl endopeptidases, are stabilized by covalent PEG modification. | 2009-12-10 |
20090304755 | PHARMACEUTICAL FORMULATION OF LOSARTAN - A pharmaceutical composition comprising losartan and pharmaceutically acceptable salts thereof and a process of forming the same. The pharmaceutical composition of losartan comprises an active agent comprising an effective amount of losartan or its pharmaceutical salt thereof, and pharmaceutically acceptable additives, wherein d(0.9) of losartan is less than 50μ and/or specific surface area is more than 0.6 m | 2009-12-10 |
20090304756 | Method for the Encapsulation and Controlled Release of Poorly Water-Soluble (Hyprophobic) Liquid and Solid Active Ingredients - The invention relates to the filling of hydrophobic or hydrophobically modified porous microparticles with hydrophobic substances with subsequent encapsulation of the resulting hydrophobic particles using layer-by-layer (LbL) polyelectrolyte technology for the purpose of preparing homogeneous suspensions in water, and also for the controlled release of the encapsulated active ingredients. Through a specific modification of the LbL surface it is possible to realize preferred adhesion at the target site. | 2009-12-10 |
20090304757 | Cosmetic Compositions Comprising A Powdered Thermoplastic - The present invention relates to cosmetic compositions used in particular in the care and makeup field. The invention relates to cosmetic compositions for making up and/or caring for keratin materials such as the skin, lips, nails, head hair, eyelashes, eyebrows or body hair of human beings. It relates more particularly to cosmetic compositions comprising a powdered thermoplastic polymer, and also to the use of this powder for improving the properties of cosmetic compositions. | 2009-12-10 |
20090304758 | Formulations of lipoic acid and hyaluroinc acid and/or the derivatives thereof in the pharmaceutical and cosmetic fields - The present invention relates to novel formulations comprising lipoic acid and hyaluronic acid and/or the derivatives thereof for use in the repair of chronic ulcers, the regeneration of damaged skin, the prevention of skin aging and, when administered by the systemic route, to treat peripheral neuropathies and intoxications by chemical and/or biological agents. | 2009-12-10 |
20090304759 | CHITOSAN/SUGAR COMPOSITE FILMS AND LAMINATES MADE THEREFROM - Low-shrinkage chitosan films containing sugars and laminates made from the films are provided. The films and laminates can be used to make a variety of finished articles that can be used to provide protection from hazardous chemical and biological agents. | 2009-12-10 |
20090304760 | Biocidal Film-Forming Composition and Method for Coating Surfaces With It - A biocidal film-forming composition comprising, a nitrogen-containing biocide, a sulphur-containing biocide, an oleophilic carrier, and a film-forming agent. The invention also includes a method of coating an item with that composition. The present invention provides for the manufacture of solid items from plastics materials in which the biocidal composition has been included. | 2009-12-10 |
20090304761 | FUNCTIONALLY GRADED BIOCOMPATIBLE COATING AND COATED IMPLANT - The present invention provides a biocompatible coating comprising calcium phosphate that is functionally graded across the thickness of the coating. The coating, which preferably includes hydroxyapatite, is particularly useful for coating implants, such as dental or orthopedic implants. The functionally graded coating is generally crystalline near the interface with the surface of the implant, with crystallinity and crystal diameter decreasing toward the outer layer of the coating. The invention further provides methods for preparing a coated implant comprising a functionally graded calcium phosphate coating thereon. Furthermore, an antimicrobial agent can be dispersed within the calcium phosphate coating at discrete locations to provide for a coating with tailored release of the antimicrobial agent. | 2009-12-10 |
20090304762 | Antimicrobial thermoplastic molding composition - A thermoplastic composition having antimicrobial and good impact properties is disclosed. The composition comprises (i) (co)polycarbonate, (ii) (co)polyester, (iii) grafted elastomeric (co)polymer and an amount of an antimicrobial agent. The antimicrobial agent that contains zeolite, metal oxide and hydrotalcite is present in an amount sufficient to impart to the composition antimicrobial efficacy. | 2009-12-10 |
20090304763 | Insect Attractant Composition - This invention relates to a liquid insect attractant composition containing at least one C | 2009-12-10 |
20090304764 | Bone Regeneration Element for Stabilising Artificial Tooth Roots - A bone regeneration element for stabilizing artificial tooth roots ( | 2009-12-10 |
20090304765 | R-RAS ACTIVITY IN VASCULAR REGULATION - The invention provides means and methods for vascular regulation through enhancement or inhibition of R-Ras activity. The invention specifically provides means and methods for promoting a quiescent state of a vascular cell by providing additional R-Ras activity to the cell. The invention further provides means and methods for diagnosing a condition of vasculature of an individual. | 2009-12-10 |
20090304766 | LOCALIZED DELIVERY OF DRUG COMBINATIONS - Implants comprising controlled delivery matrices, associated with, or including medical devices, having stably and releasably associated therewith predetermined non-antagonistic combinations of two or more therapeutic agents provide control of the ratio of these agents at a localized site. Methods of identifying such combinations are also disclosed. | 2009-12-10 |
20090304767 | Bio-Degradable Block Co-Polymers for Controlled Release - A block or graft copolymer includes a first block, and a second block different from the first block, wherein the first block is a poly(lactide-glycolide) copolymer. The polymers may be formulated in compositions with drug components for use in coating medical devices such as stents. Different blocks of the block or graft copolymer degrade in the body at different rates. The drug release profile from the coating is a combination the individual release rates of the different blocks and so can be controlled by controlling the selection and relative amounts of the respective blocks. | 2009-12-10 |
20090304768 | Gastro-Retentive System for the Delivery of Macromolecules - The present invention provides a gastro-retentive delivery assembly (GRDA) comprising a folded multi-layered device comprising a macromolecule-containing compartment bordered by enveloping layers and one or more enforcing strips, the device being adapted to unfold when in a subject's stomach, whereupon unfolding, the macromolecule is released from said device via at least one aperture in an enveloping layer. The invention also provides a method for gastroretentive delivery of macromolecules via the GRDA of the invention; a method of preparing the GRDA of the invention as well as a method for treating a subject for a pathological condition, making use of the GRDA of the invention. | 2009-12-10 |
20090304769 | METHODS FOR IDENTIFYING AGENTS AND THEIR USE FOR THE PREVENTION OF RESTENOSIS - Agents that inhibit or prevent restenosis are identified by assaying test agents in a battery of assays to measure the effect of the test agent on cell proliferation, thrombosis, tissue modeling, and inflammation. Treatment for restenosis is provided using compositions of the invention. | 2009-12-10 |
20090304770 | POLYMER - A novel class of polymers obtainable by copolymerising a monomer mixture comprising (i) hydrophilic monomer of general formula (I) Y—B—X; (ii) styrene or a substituted styrene, a monomer or mixture of monomers which when polymerised form a polymer with a Tg lower than the Tg of a homopolymer of monomer (I) and lower than the Tg of a homopolymer of monomer (ii); and a monomer having a crosslinkable group is described. The invention also relates to a method for producing such polymers, implants coated with the polymers and methods for forming the same. | 2009-12-10 |
20090304771 | Local Delivery System for the Chemotherapeutic Drug Paclitaxel - The present invention provides methods for producing a semi-degradable polymeric composite drug delivery device for localized delivery of chemotherapeutic agents to be used in conjunction with total vertebral body replacement surgery that requires placement of a vertebral replacement cage for the treatment of a spinal neoplasm. | 2009-12-10 |
20090304772 | IMPLANTABLE MATERIALS HAVING ENGINEERED SURFACES AND METHOD OF MAKING SAME - Implantable materials having engineered surfaces and method of making same comprising geometric features on at least one surface of the material having at least one of chemical, physiochemical and electrochemical activity different than regions of the at least one surface without the features. | 2009-12-10 |
20090304773 | SURGICAL ADHESIVE AND USES THEREFORE - The present invention provides a liquid polymer composition which can be implanted into a living mammal and which forms a solid hydrogel by in situ polymerization upon contact with body fluid and tissue. The composition also can be used as a coating on a medical device, or for the formation of a medical device. Formation of a solid implant or coating involves crosslinking of the adhesive with itself and with surrounding tissue. The liquid implant, by itself or in conjunction with various prostheses, can be used for many purposed, including fixation of the urethra for providing treatment for incontinence, and repair of herniations in the abdominal cavity, including rectocele, cystocele, enterocele, and inguinal hernia. The adhesive may be used to establish adhesion prevention during such repairs, in part by coating or being the material of a repair mesh. | 2009-12-10 |
20090304774 | IMPLANTABLE DEVICES HAVING CERAMIC COATING APPLIED VIA AN ATOMIC LAYER DEPOSITION METHOD - Substrates coated with films of a ceramic material such as aluminum oxides and titanium oxides are biocompatible, and can be used in a variety of applications in which they are implanted in a living body. The substrate is preferably a porous polymer, and may be biodegradable. An important application for the ceramic-coated substrates is as a tissue engineering scaffold for forming artificial tissue. | 2009-12-10 |
20090304775 | Drug-Exuding Orthopedic Implant - An apparatus in accordance with the present invention may include an orthopedic implant having one or more voids integrated into a surface thereof. A beneficial agent may be deposited into each void, and a regulator element may substantially cover an open end of thereof. In this manner, the regulator element may regulate delivery of the beneficial agent through the open end of the voids over a period of time. | 2009-12-10 |
20090304776 | TRANSMUCOSAL DELIVERY OF THERAPEUTIC AGENTS AND METHODS OF USE THEREOF - Described herein is a transmucosal delivery device and their use for delivering bioactive agents across a mucosal membrane. The delivery devices contain a pharmaceutically acceptable oxidizing and agents that facilitates the delivery of the blood stream across the mucosal membrane. | 2009-12-10 |
20090304777 | AGENT ADMINISTRATION - An intra-ruminal bolus and method of manufacture is described that releases a therapeutically effective amount of at least one beneficial agent to a ruminant animal over a time period of less than approximately 21 days. The bolus includes at least one beneficial agent, at least one densifier material, at least one binding agent, and at least one releasing agent. The bolus is manufactured using a ratio of binding agent to releasing agent that is tailored to achieve the desired rate of release and timing of delivery. This ratio is in the order of approximately 1 part binding agent to between approximately 0.01 and approximately 2 parts releasing agent and may be varied within this range in order to obtain the preferred release length of time. The bolus is particularly useful for delivery of anti-parasitic compounds but may also be used for delivery of other active agents such as trace elements including selenium and cobalt. | 2009-12-10 |
20090304778 | Diagnostics and Methods for Removal and Detection of Interferents - Described herein are substrates, methods, articles, and kits that are useful for removing interferents from samples for diagnostic purposes. The interferents are removed with phosphocellulose and cation exchange materials. These materials could also be used in vitro to improve the performance of a diagnostic assay or in vivo to remove the interferents. | 2009-12-10 |
20090304779 | MICRO-MEMBRANE IMPLANT WITH CUSPED OPENING - Precut, user-shapeable, resorbable polymer micro-membranes having cusped orifices are disclosed. The micro-membranes are constructed of resorbable polymers, which are engineered to attenuate adhesions. The membranes can formed to have very thin thicknesses, for example, thicknesses between about 0.010 mm and about 0.300 mm, while maintaining adequate strength. The membranes can be extruded from polylactide polymers having a relatively high viscosity property, can be stored in sterile packages, and can be preshaped with relatively high reproducibility during implantation procedures. | 2009-12-10 |
20090304780 | WOUND DRESSINGS INCORPORATING HONEY - An improved wound dressing using a honey composition is provided. Preferably, the honey composition includes buckwheat honey. | 2009-12-10 |
20090304781 | MASTER GENE OF ARTERIOGENESIS - The present invention relates to a pharmaceutical composition comprising (a) a polynucleotide comprising or consisting of a nucleotide sequence encoding a polypeptide with the amino acid sequence as set forth in SEQ ID NO: 2; (b) a polynucleotide comprising or consisting of a nucleotide sequence which is a fragment of a nucleotide sequence encoding the polypeptide with the amino acid sequence as set forth in SEQ ID NO: 2, wherein the polypeptide encoded by said polynucleotide has arteriogenic activity; (c) a polynucleotide comprising or consisting of a nucleotide sequence encoding a polypeptide, wherein said polypeptide exhibits at least 70% sequence identity with the sequence of the polypeptide encoded by the polynucleotide of (a) or (b) over the entire length, and wherein said polypeptide has arteriogenic activity; and/or (d) a polypeptide encoded by the polynucleotide of any one of (a) to (c). | 2009-12-10 |
20090304782 | Topical Ibuprofen Formulation - The present invention relates to a liposomal liquid pharmaceutical composition comprising ibuprofen, at least one phospholipid, at least one C | 2009-12-10 |
20090304783 | COMPOSITIONS AND METHODS FOR TREATING BACTERIA - The present invention relates to the field of bacteriology. In particular, the present invention provides compositions (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of treating (e.g., killing or inhibiting growth of) bacteria. For example, the present invention provides pharmaceutical compositions (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of using the same in research, therapeutic and drug screening applications. | 2009-12-10 |
20090304784 | SEAMLESS CAPSULES CONTAINING HIGH AMOUNTS OF POLYUNSATURATED FATTY ACIDS AND A FLAVOURING COMPONENT - A seamless capsule includes a core and a shell, wherein the core includes at least one polyunsaturated fatty acid, and at least one flavouring component, the process for manufacturing the capsule and products containing the capsule are also disclosed. | 2009-12-10 |
20090304785 | ESCALATING DOSING REGIMEN FOR EFFECTING WEIGHT LOSS AND TREATING OBESITY - The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions. | 2009-12-10 |
20090304786 | Stable Dosage Forms of an Antidepressant - The present invention relates to stable solid dosage forms of an antidepressant. More particularly, the present invention relates to stable solid dosage forms of bupropion hydrochloride. The present invention also relates to a process for the preparation of stable solid dosage forms of bupropion hydrochloride. | 2009-12-10 |
20090304787 | DRUG DELIVERY COMPOSITION - A drug delivery composition that comprises extruded spheroids. The spheroids comprise at least one active pharmaceutical ingredient; at least one extrusion-spheronization aid; at least one superdisintegrant; and at least one glidant, at least one lubricant, and/or at least one oil. The spheroids may also be coated. In a further aspect, a drug delivery composition that comprises coated spheroids that have inert spheroids and at least one coating for the spheroids. The coating comprises at least one active pharmaceutical ingredient and at least one superdisintegrant. | 2009-12-10 |
20090304788 | ENCAPSULATED MATERIALS AND METHODS FOR ENCAPSULATING MATERIALS - A system that incorporates teachings of the present disclosure may include, for example, an apparatus having an outer nozzle operable to discharge an outer stream of a shell solution, and an inner nozzle operable to discharge an inner stream of a core solution intermixed with a plurality of materials. The outer stream can substantially surrounds the inner stream, thereby forming a combined stream. A plurality of capsules can be formed responsive to a force applied to the combined stream. At least a portion of the plurality of capsules are desirable capsules, each having a core encapsulated by a portion of the shell solution. The core can have at least one of the plurality of materials encapsulated by a portion of the core solution without protruding an outer surface of the portion of the shell solution. Additional embodiments are disclosed. | 2009-12-10 |
20090304789 | NOVEL TOPIRAMATE COMPOSITIONS AND AN ESCALATING DOSING STRATEGY FOR TREATING OBESITY AND RELATED DISORDERS - The present invention is drawn to novel topiramate compositions as well as methods for treating obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention also features a pharmaceutical composition that includes, e.g., topiramate alone or in combination with a sympathomimetic agent and a novel escalating dosing strategy for administering such compositions. | 2009-12-10 |
20090304790 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER - The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects. | 2009-12-10 |
20090304791 | SOLID ORAL FORMS OF EBASTINE - The invention relates to compositions in the form of matrices consisting of solid ebastine dispersions in nonionic surfactants having a HLB of between 10 and 20 and a melting point of between 30° C. and 70° C. The invention also relates to solid oral pharmaceutical forms of ebastine containing said matrices, particularly tablets, and having good solubility and bioavailability properties and improved stability. | 2009-12-10 |
20090304792 | GRANULE AND ORALLY DISINTEGRATING TABLET COMPRISING OXYCODONE - The present invention relates to granules comprising oxycodone, as well as to orally disintegrating tablets including same and optionally acetaminophen. | 2009-12-10 |
20090304794 | CONTROLLED RELEASE FORMULATIONS OF PRAMIPEXOLE - A controlled release formulation of pramipexole for once-a-day administration to a mammalian subject, which formulation releases pramipexole along a pre-determined release profile, is provided. | 2009-12-10 |
20090304795 | TABLETS WITH IMPROVED DRUG SUBSTANCE DISPERSIBILITY - The present invention relates to a method for the preparation of pharmaceutical compositions in the form of tablets with improved drug substance dispersibility, which method comprises
| 2009-12-10 |
20090304796 | Nanoparticle suitable for delivery of a biomolecule into or out of a membrane enclosed cell or cell organelle - A nano sized particle for in vitro or ex vivo biomolecule delivery to cell cultures through heat induced endosomal release comprising a superparamagnetic core coated in a heat sensitive coating, comprising membrane disruptive components and binding sites for attachment of biomolecules and markers to be delivered is provided. A method is provided for introducing the release effect of a plurality of said biomolecule and endosomal disrupture molecules by applying an alternating field to a cell culture harbouring the particle described by the invention. | 2009-12-10 |
20090304797 | Process for the Preparation of Micronized Valsartan - The present invention relates to process for preparing micronized Valsartan with particle size distribution of d | 2009-12-10 |
20090304798 | Methods and compositions for therapeutic use of RNA interference - The present invention provides methods and compositions for attenuating expression of a target gene in vivo. In general, the method includes administering RNAi constructs (such as small-interfering RNAs (i.e., siRNAs) that are targeted to particular mRNA sequences, or nucleic acid material that can produce siRNAs in a cell), in an amount sufficient to attenuate expression of a target gene by an RNA interference mechanism, e.g., in a sequence-dependent, PKR-independent manner. In particular, the subject method can be used to alter the growth, survival or differentiation of cells for therapeutic and cosmetic purposes. | 2009-12-10 |
20090304799 | NANOEMULSION INFLUENZA VACCINE - The present invention relates to methods for inducing an immune response to influenza in a subject comprising administering a nanoemulsion vaccine composition comprising an influenza immunogen or protein. | 2009-12-10 |
20090304800 | Dry Coating using Twin-Screw Kneader - An object of the present invention is to provide a dry coating process that can produce a dry-coated preparation in a large amount. A large amount of dry-coated preparation can be produced more efficiently, than by prior-art processes, by a process in which a material containing core particles and a dry binder (lauric acid, myristic acid, or the like) is kneaded in a twin-screw kneader to produce dry binder particles in which the surfaces of the core particles are dry-coated with the dry binder. Further, a dry coating particle production process in which a material containing core particles, a dry binder, and a coating powder is kneaded in a twin-screw kneader can also produce a large amount of dry-coated preparation more efficiently than prior-art processes. | 2009-12-10 |
20090304801 | AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE - Described are nanoparticulate formulations of a benzodiazepine, such as lorazepam, that does not require the presence of polyethylene glycol and propylene glycol as stabilizers, and methods of making and using such formulations. The formulations are particularly useful in aerosol and injectable dosage forms, and comprise nanoparticulate benzodiazepine, such as lorazepam, and at least one surface stabilizer. The formulations are useful in the treatment of status epilepticus, treatment of irritable bowel syndrome, sleep induction, acute psychosis, and as a pre-anesthesia medication. | 2009-12-10 |
20090304802 | NASAL DELIVERY - A sustained release nasal formulation for delivery to a nasal cavity of a subject, wherein the formulation provides for sustained release of a substance, in particular nitric oxide (NO), to nasal mucosa within the nasal cavity so as to provide one or both of a therapeutic effect and promote normal nasal function, and a nasal delivery device and method relating thereto. | 2009-12-10 |
20090304803 | Compositions and methods relating to target-specific photodynamic therapy - The invention generally provides methods and compositions useful for providing photodynamic therapy to specific cells or tissues. | 2009-12-10 |
20090304804 | Biologic devices for hemostasis - A microscopic protein device and the method of manufacture and the use of such a device for hemostasis. The device, made with biologic material such as serum albumin from a human or animal source, is less than five micron in any one dimension and typically less than one micron in diameter. It does not have any other biological or drug molecules attached to it in vitro. However, the device has properties that allow it to capture, concentrate, carry or bind biomodifying molecules, such as coagulation factor(s), or potentially other drugs, after exposure to plasma in vitro; and possibly in vivo as well. After infusion of said device intravenously inside the body, hemostatic effects can be demonstrated. | 2009-12-10 |
20090304805 | COMBINATIONS AND MODES OF ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY - The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents (such as an anti-VEGF antibody), or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime. | 2009-12-10 |
20090304806 | Pharmaceutical Compositions - A process for the production of a composition comprising a water-insoluble sartan which comprises the steps of: a) providing a mixture comprising: i) a water-insoluble sartan, ii) a water soluble carrier, iii) a solvent for each of the sartan and the carrier, and b) spray-drying the mixture to remove the or each solvent and obtain a substantially solvent-free nano-dispersion of the sartan in the carrier. | 2009-12-10 |
20090304807 | METHOD FOR PREPARING A PRION-FREE BOND GRAFTING SUBSTITUTE - The present invention relates to a method for preparing a bone graft substitute using bovine bone, and more particularly to a method for preparing a safe bone graft substitute which does not have the risk of infection with bovine spongiform encephalopathy, the method comprising treating bovine bone with sodium hypochlorite and treating the treated bone at a high temperature of more than 600° C. The bone graft substitute does not cause an immune response, because it is prepared by effectively removing lipids and organic substances from bovine bone having a structure very similar to that of the human bone. Also, it has excellent osteoconductivity, and is free of prion, and thus it does not have the risk of infection with bovine spongiform encephalopathy. According to the disclosed invention, the bone graft substitute having such advantages can be prepared in a simple manner. | 2009-12-10 |
20090304808 | Anti-cancer immune-modulating agent - The present invention discloses a method for the preparation of an anti-cancer composition from umbilical cord tissue and animal embryonic tissues, the latter preferably obtained from different animal classes. The composition obtainable by the method comprises different embryonic antigens and is used in therapy and prophylaxis of any type of cancer. | 2009-12-10 |
20090304809 | DENTAL FILLERS, METHODS, COMPOSITIONS INCLUDING A CASEINATE - The present application provides dental fillers, and methods of making and using dental fillers that include a treated surface that includes a caseinate. Dental compositions including such dental fillers can be useful for delivering ions to the oral environment. Dental compositions, and methods of using dental compositions that include a caseinate and a hardenable resin or a water-dispersible, polymeric film former are also provided. | 2009-12-10 |
20090304810 | Composition and method for enhanced sanitation and oxidation of aqueous systems - Compositions and methods for their use are presented that substantially increase the rate of inactivation of microbiological organisms, especially those resistant to inactivation from free halogen based sanitizers, and oxidation of oxidation resistant organic based compounds in aqueous solution. Aquatic facilities susceptible to accumulation of organic N-chloramines, cyanuric acid and other oxidation resistant compounds, as well as oxidation resistant parasitic organisms such as cryptosporidium and Giardia, obtain dramatic improvements in the rate of oxidation and subsequent inactivation of these undesirable contaminants | 2009-12-10 |
20090304811 | Pharmaceutical Formulations Comprising Stabilized Polysaccharides and Source of Hydrogen Peroxide - A pharmaceutical formulation that is effective in adversely affecting the viability of microorganisms or in inhibiting their growth and that provides better safety and/or comfort to the users comprises a polysaccharide, a source of hydrogen peroxide, and an anti-oxidant. The formulation can further comprise a chelating agent and/or an ophthalmically active agent for treating or controlling a disease or disorder of the eye. The formulation may be used to treat, clean, disinfect, store, wet, or rewet contact lenses. | 2009-12-10 |
20090304812 | Topical Pharmaceutical Compositions - The present invention relates to compositions and applicator devices for providing accurate and localized administration of pharmaceutical compositions containing therapeutic agents to the skin. In particular, the invention relates to compositions which are solid at a temperature of about 250 C or less, and which soften upon continuous contact with the skin of a patient. The present invention allows a user to administer precise doses of a therapeutic agent by highly localized application of the composition to a desired skin region, without contacting surrounding skin regions, or the user's hand. | 2009-12-10 |
20090304813 | VIRUCIDAL COMPOSITIONS AND USES - A composition for use in treating or preventing a respiratory virus which comprises: (a) at least one water soluble zinc, copper, selenium and/or manganese compound able in aqueous solution to dissociate into zinc, copper selenium and/or manganese ions; (b) at least one water soluble ammonium agent able in aqueous solution to dissociate into ammonium ions (c) at least one acid, and (d) water. | 2009-12-10 |
20090304814 | FIBRILLATION RESISTANT PROTEINS - Protection of proteins against fibrillation may be afforded by introduction of certain histidine substitutions into the protein, such that a pair of histidines are present with sufficient spacing as to allow the histidines to coordinate with zinc. In the case of insulin, introduction of histidine residue substitutions at residues A4 and A8 together or a histidine residue substitution at residue B1, provides increased resistance to fibrillation while maintaining at least a majority of the activity of the insulin analogue. Introduction of a histidine residue substitution at residue A8 restores at least a portion of fibrillation resistance that may have been harmed by substitutions present on the B-chain such as those present in fast-acting insulins. Proteins protected by such histidine substitutions may be used to provide a pharmaceutical composition. A method of treating a patient includes administering a physiologically effective amount of the pharmaceutical composition to the patient. | 2009-12-10 |
20090304815 | METHOD OF TREATMENT FOR MUSCULAR DYSTROPHY - The invention relates to a method of treatment for muscular dystrophies, including Duchenne, Becker, limb-girdle, facioscapulohumeral, congenital muscular dystrophies and the like using a combination of nitric oxide-releasing and anti-inflammatory compounds. | 2009-12-10 |
20090304816 | METHOD AND COMPOSITION FOR TREATING AND DIAGNOSING RESTLESS LEGS SYNDROME - A method of treating Restless Legs Syndrome (RLS) comprises the joint administration of an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent, in particular pramipexole, and iron in a biologically usable form, in pharmacologically effective combined amounts. Also disclosed is a corresponding use; a pharmaceutical composition comprising an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent, in particular pramipexole, and iron in a biologically usable form, and a pharmaceutically acceptable carrier; a package comprising a pharmaceutical composition for per-oral administration comprising an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent and a pharmaceutically acceptable carrier and a pharmaceutical composition for per-oral administration comprising iron in a biologically usable form and a pharmaceutical acceptable carrier. | 2009-12-10 |